Neuralstem, Inc. is now set to begin a Phase I safety trial to treat chronic spinal cord injury (cSCI) with its NSI-566 stem cells. The NSI-566/cSCI Phase I trial will enroll patients with thoracic spinal cord injuries (T2-T12) who have an American Spinal Injury Association (AIS) A level of impairment, between one and two years after injury.
“In animals, we have shown compelling proof-of-principle of return of significant function. With 30 successful spinal surgeries completed in our ALS trials, we feel we are ready to tackle spinal cord injury”, said Karl Johe PhD, Neuralstem’s Chairman of the Board and Chief Scientific Officer.